Profiling trial burden and patients' attitudes to improve clinical research in epidermolysis bullosa.
Challenges for trial design
Clinical trial
Epidermolysis bullosa
Rare disease
Recruitment failures
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
10 07 2020
10 07 2020
Historique:
received:
14
02
2020
accepted:
16
06
2020
entrez:
12
7
2020
pubmed:
12
7
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Epidermolysis bullosa (EB) comprises inherited mechanobullous dermatoses with considerable morbidity and mortality. While current treatments are symptomatic, a growing number of innovative therapeutic compounds are evaluated in clinical trials. Clinical research in rare diseases like EB, however, faces many challenges, including sample size requirements and recruitment failures. The objective of this study was to determine attitudes of EB patients towards clinical research and trial participation as well as the assessment of contextual motivating and discouraging factors in an effort to support patient-centered RD trial designing. A 53-items questionnaire was handed over to EB patients (of all types and ages) in contact with the EB House Austria, a designated national center of expertise for EB care. Main categories included level of interest in and personal knowledge about clinical studies, pros/cons for participation and extent of individual expenses considered acceptable for participation in a clinical study. Descriptive subgroup analysis was calculated with SPSS 20.0 and Microsoft Excel. Thirty-six individuals (mean age 25.7 years), diagnosed for recessive dystrophic EB (36.1%), EB simplex (33.4%), junctional EB (8.3%), dominant dystrophic EB (2.8%) and acral peeling syndrome (2.8%) participated. Motivation for participation in and the desire to increase personal knowledge about clinical trials were (outmost) high in 57.2 and 66.7%, respectively. Altruism was the major motivating factor, followed by hope that alleviation of the own symptoms can be achieved. The greatest hurdle was travel distance, followed by concerns about possible adverse reactions. Patients diagnosed for severe subgroups (RDEB, JEB) were more impaired by the extent of scheduled invasive investigations and possible adverse reactions of the study medication. Patients with generally milder EB forms and older patients were accepting more frequent outpatient study visits, blood takes, skin biopsies and inpatient admissions in association with trial participation. This study provides additional indications to better determine and address attitudes towards clinical research among EB patients as well as guidance to improve clinical trial protocols for patient centricity.
Sections du résumé
BACKGROUND
Epidermolysis bullosa (EB) comprises inherited mechanobullous dermatoses with considerable morbidity and mortality. While current treatments are symptomatic, a growing number of innovative therapeutic compounds are evaluated in clinical trials. Clinical research in rare diseases like EB, however, faces many challenges, including sample size requirements and recruitment failures. The objective of this study was to determine attitudes of EB patients towards clinical research and trial participation as well as the assessment of contextual motivating and discouraging factors in an effort to support patient-centered RD trial designing.
METHODS
A 53-items questionnaire was handed over to EB patients (of all types and ages) in contact with the EB House Austria, a designated national center of expertise for EB care. Main categories included level of interest in and personal knowledge about clinical studies, pros/cons for participation and extent of individual expenses considered acceptable for participation in a clinical study. Descriptive subgroup analysis was calculated with SPSS 20.0 and Microsoft Excel.
RESULTS
Thirty-six individuals (mean age 25.7 years), diagnosed for recessive dystrophic EB (36.1%), EB simplex (33.4%), junctional EB (8.3%), dominant dystrophic EB (2.8%) and acral peeling syndrome (2.8%) participated. Motivation for participation in and the desire to increase personal knowledge about clinical trials were (outmost) high in 57.2 and 66.7%, respectively. Altruism was the major motivating factor, followed by hope that alleviation of the own symptoms can be achieved. The greatest hurdle was travel distance, followed by concerns about possible adverse reactions. Patients diagnosed for severe subgroups (RDEB, JEB) were more impaired by the extent of scheduled invasive investigations and possible adverse reactions of the study medication. Patients with generally milder EB forms and older patients were accepting more frequent outpatient study visits, blood takes, skin biopsies and inpatient admissions in association with trial participation.
CONCLUSIONS
This study provides additional indications to better determine and address attitudes towards clinical research among EB patients as well as guidance to improve clinical trial protocols for patient centricity.
Identifiants
pubmed: 32650809
doi: 10.1186/s13023-020-01443-3
pii: 10.1186/s13023-020-01443-3
pmc: PMC7350741
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
182Références
J Genet Couns. 2018 Apr;27(2):470-480
pubmed: 29130143
BMJ. 1996 Jan 13;312(7023):71-2
pubmed: 8555924
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
J Health Econ. 2000 May;19(3):403-20
pubmed: 10977197
Patient Prefer Adherence. 2016 Apr 27;10:631-40
pubmed: 27175063
Hastings Cent Rep. 1987 Apr;17(2):20-4
pubmed: 3294743
Am J Med Genet C Semin Med Genet. 2016 Dec;172(4):313-331
pubmed: 27862920
Respir Med. 2010 Apr;104(4):578-83
pubmed: 19962873
Annu Rev Genomics Hum Genet. 2013;14:579-95
pubmed: 23875802
Clin Exp Dermatol. 2002 Nov;27(8):707-10
pubmed: 12472552
Orphanet J Rare Dis. 2018 Apr 23;13(1):61
pubmed: 29688860
J Eur Acad Dermatol Venereol. 2019 May;33(5):e217-e219
pubmed: 30472803
Ther Innov Regul Sci. 2018 Mar;52(2):220-229
pubmed: 29714515
BMC Health Serv Res. 2014 Feb 26;14:89
pubmed: 24568690
Soc Sci Med. 1999 Apr;48(8):977-88
pubmed: 10390038
Stat Methods Med Res. 2002 Oct;11(5):413-27
pubmed: 12357587
Br J Dermatol. 2009 Oct;161(4):869-77
pubmed: 19624546
Cold Spring Harb Perspect Biol. 2020 May 1;12(5):
pubmed: 31653644
J Am Acad Dermatol. 2014 Jan;70(1):89-97.e1-13
pubmed: 24355263
Br J Dermatol. 2018 May;178(5):1128-1134
pubmed: 29341069
BMJ Open. 2017 Mar 20;7(3):e015276
pubmed: 28320800
Mol Diagn Ther. 2020 Jun;24(3):299-309
pubmed: 32328988
Eur J Cancer Care (Engl). 2015;24(1):133-41
pubmed: 24467443
J Child Neurol. 2013 Sep;28(9):1142-50
pubmed: 24014509
J Invest Dermatol. 2020 Sep;140(9):1681-1687
pubmed: 32428541
Blood Transfus. 2015 Apr;13(2):302-9
pubmed: 25369591
Qual Life Res. 2020 Jul;29(7):1731-1745
pubmed: 32246433
JAMA Intern Med. 2016 Dec 1;176(12):1826-1833
pubmed: 27723879
J Oncol Pract. 2013 Nov;9(6):287-93
pubmed: 24130251
Orphanet J Rare Dis. 2019 Feb 8;14(1):36
pubmed: 30736861
J Epidemiol Community Health. 2005 May;59(5):342-5
pubmed: 15831678
Drug Discov Today. 2019 Mar;24(3):867-872
pubmed: 30658132
Lancet Oncol. 2006 Feb;7(2):141-8
pubmed: 16455478
Am J Bioeth. 2007 Mar;7(3):12-5
pubmed: 17366221
Br J Dermatol. 2009 Dec;161(6):1323-30
pubmed: 19681875
Orphanet J Rare Dis. 2019 Feb 7;14(1):31
pubmed: 30732630
Adv Wound Care (New Rochelle). 2014 Jul 1;3(7):468-475
pubmed: 25032066
Trials. 2018 May 10;19(1):291
pubmed: 29793540
BMJ. 1999 Apr 24;318(7191):1114-7
pubmed: 10213724
PLoS Med. 2007 Nov 27;4(11):e324
pubmed: 18044980
Exp Dermatol. 2019 Oct;28(10):1176-1189
pubmed: 31140655
Am J Bioeth. 2002 Spring;2(2):3-9
pubmed: 12189059
Pediatr Dermatol. 2015 Jan-Feb;32(1):41-52
pubmed: 24650374
Orphanet J Rare Dis. 2018 Nov 6;13(1):195
pubmed: 30400970
Clin Trials. 2018 Apr;15(2):139-148
pubmed: 29475375
Orphanet J Rare Dis. 2016 Jun 14;11(1):78
pubmed: 27301273
Trials. 2006 Apr 07;7:9
pubmed: 16603070
Exp Dermatol. 2019 Oct;28(10):1146-1152
pubmed: 29679399
Cochrane Database Syst Rev. 2018 Feb 22;2:MR000013
pubmed: 29468635
Support Care Cancer. 2013 Nov;21(11):3137-42
pubmed: 23864288
Br J Dermatol. 2020 Oct;183(4):614-627
pubmed: 32017015
Br J Dermatol. 2009 May;160(5):1057-65
pubmed: 19434791
PLoS One. 2018 May 17;13(5):e0197513
pubmed: 29771953